Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Short Interest Update

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 20,045 shares, a growth of 660.7% from the April 15th total of 2,635 shares. Currently, 3.7% of the company’s shares are short sold. Based on an average daily volume of 242,685 shares, the short-interest ratio is currently 0.1 days.

Sigyn Therapeutics Price Performance

SIGY stock opened at $0.04 on Thursday. The business’s 50-day moving average is $0.04 and its two-hundred day moving average is $0.89. The firm has a market capitalization of $95,250.00 and a P/E ratio of -0.01. Sigyn Therapeutics has a 1 year low of $0.01 and a 1 year high of $5.00.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.